Home/Sulfateq/Hans Bruining

HB

Hans Bruining

Chief Financial Officer

Therapeutic Areas

Neurodegeneration Chronic Kidney Disease Cardiovascular Disease Pulmonary Disease

Sulfateq Pipeline

Drug	Indication	Phase
SUL-238	Parkinson's Disease (Mitochondrial Dysfunction)	Phase 2
SUL-150	Diabetic Kidney Disease, COPD, Heart Failure, Neurodegeneration	Preclinical
SUL-151	Diabetic Kidney Disease, COPD, Heart Failure, Neurodegeneration	Preclinical

Leadership Team at Sulfateq

Kees van der Graaf

Chief Executive Officer

Chief Operating Officer

Chief Scientific Officer

Chair, Scientific Advisory Board

View full Sulfateq profile